Masimo Corporation (Masimo), a company for noninvasive patient monitoring technologies, announced that Childrens Hospital Los Angeles has completed its system-wide conversion to Masimo SET pulse oximetry technology.

Masimo SET has been clinically proven in more than 100 independent and objective studies to provide the most trustworthy SpO2 and pulse rate measurements, even under the most difficult clinical conditions of patient motion and low peripheral perfusion, conditions common to infants and children. Its sensitivity and specificity, combined with a validated accuracy to oxygen saturations as low as 60% on patients, including cyanotic patients, helps clinicians keep their tiniest, most vulnerable patients safe. Masimo SET pulse oximetry aids the detection of congenital heart disease (CHD) and helps significantly reduce eye damage and blindness caused by retinopathy of prematurity (ROP).

Randall Wetzel, M.D., Chair of Anesthesiology and Critical Care Medicine at Childrens Hospital Los Angeles, said: Standardizing to Masimo SET allows us to more accurately assess oxygenation in children to detect life-threatening conditions earlier. It also provides a unique platform for growth with the opportunity to use Masimo Rainbow SET noninvasive measurements, such as continuous hemoglobin measurement. The ability to measure hemoglobin continuously during surgery will enable us to identify trends earlier and to more quickly and effectively manage blood and fluid administration interoperatively and in the ICUs.

In the past five years, approximately 900 hospitals in the US have converted completely to Masimo. In addition, more than half of the top hospitals listed on the US News & World Report ‘Best Hospitals Honor Roll’, including four of the top five, rely on Masimo SET pulse oximetry to provide the best care to their patients.